Member Info for DeBull

I've been expecting something since 6th July, so law of averages states we must be getting something soon....

As stated before, Certara are 1 of approx 5 companies that are now on the Project Optimus train, they are the largest i believe? Physiomics are also one of those 5.

For PYC to "review" their paper is a good sign. What would be great is if Certara reviewed on of PYC's.

No RNS's since early July. This is the longest period of no RNS's since May 2022 when there was only 1 RNS in a 4 month period.

Https://x.com/Physiomics/status/1833523967723962776

Catch

@Physiomics

at #BioForward in Oxford on 24th September! 💡 Our CEO Dr. Peter Sargent will be there to discuss how our advanced modelling techniques can accelerate your #drugdevelopment journey. Book a meeting with us! https://partneringone.informaconnect.com/sign-in?eventId=783 #PYC

@OBN_UK

@OxfordTechPark

At least its not going to tug on those purse strings to get to this venue..

Post from Bicycle yesterday regarding BT5528 which i believe PYC helped with?

https://ascopubs.org/doi/10.1200/JCO.23.01107

https://x.com/Bicycle_tx/status/1831711221856211326

They are, see this from a year ago and Merck KGaA

https://www.morningstar.co.uk/uk/news/AN_1693474904768297400/in-brief-physiomics-to-extend-anti-cancer-regimen-work-with-merck.aspx

Yes Laura,

Interesting that they are starting to mention MIDD ( Model informed drug development ) and MIPD ( Model informed precision dosing ) on X. They also mention that they "specialise in developing advanced mathematical models that enhance treatment optimisation, including the dosing and scheduling of anti-cancer drugs."

I believe this is the first time they have mentioned Anti-cancer drugs for sometime?

MIDD is a FDA initiative? https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program

MIDP = https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780803/

However, the FDA do use the acronym MIPD, but that stands for Model informed product development.

Of course Laura.

Hi both, emailed PS and PYC directly, not one reply. Very frustrating.

Yes i have King, many weeks ago, but no reply, and i was very cordial.

This post by PYC just shows how they need to up their game on X and other social media platforms.

Yes, trying to get project optimus highlighted, but using the @FDA is wrong. They have only 1 post, and that 1 post says you need to refer to @ US_FDA. https://x.com/Physiomics/status/1813847167510954444

On X Certara, InsightRX & IQVIA Botech, along with Physiomics have been the most vocal on Project Optimus. Enter stage right Phastar https://x.com/TeamPhastar/status/1828402123056296387

Meanwhile on the PYC Telegram, its all out civil war. There has been some interesting info posted, but i do not know how legit it is, so i'll leave it there.

Good news for Faron, and as you say, data data data is key.

However, as much as Fast tracking is to be applauded there, CellCentric has been Granted FDA Orphan Drug Designation for Inobrodib (CCS1477). As far as i can understand, Orphan status has more benefits to a company in accessing the FDA. PYC obviously were integral in getting Inobrodib to where it is today.

+1m trade delayed yesterday, sell?

I also can not find Hitesh on X. https://x.com/hilseth_mistrov

Lots of chatter all of a sudden on Telegram PYC group.

The groups lead name has spotted this. https://www.jnj.com/media-center/press-releases/johnson-johnson-strengthens-pipeline-to-lead-in-atopic-dermatitis-with-the-completion-of-the-acquisition-of-yellow-jersey-therapeutics-gaining-ownership-of-nm26

David Snell of Numab commented on this “We have worked with Physiomics on a PK/PD modelling project for our molecule NM26-2198, intended for use in patients with inflammatory disease. The work has been highly productive, valuable and enjoyable. The Physiomics team are knowledgeable, helpful and dedicated to provide the expertise required to bring the project to fruition. Based on this excellent collaboration we will certainly be working with Physiomics again.”

Daniel Snell, VP Translational Science

Numab Therapeutics AG

So, it is thought that there could be a link between PYC and J&J, or at least they should be aware of PYC?? The Telegram post also mentions that NM26 is for inflammatory disease, and that PYC's knowledge goes beyond that of oncology?

Yes, https://web.archive.org/web/20240406001818/https://www.physiomics.co.uk/wp-content/uploads/2021/11/SITC2021-Chassagnole-15523-Final_12-11-2021.pdf

In relation to this post, it relates to their webpage, https://www.physiomics.co.uk/exposure-response-modelling/ which was first placed on the site in 2022, and was updated in April 2024, to show the diagrams and a model developed for Bicycle, according to the internet time machine.

KT So you have over 2.5m PYC shares?

&

O72, i take it, you did not partake in the purchase of £10k of YC shares today?

Thanks..... i take it this has been happening for a while now?

Some one has asked on Telegram who the "un named UK client" is that was mentioned some months ago in a contract.

A reply has come back saying Bristrol Mayers, guess they knew they'd spelt it wrong (should be Bristol Meyers Squibb) and everyone should know they are US based. I guess this reply is tongue in cheek.